Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
225 stopped studies mapped to Neuroendocrine Carcinoma and descendants · 90% state a reason
Over the 225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment… | Phase 2 / Phase 3 | suspended | May 27, 2020 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT05403723 | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Phase 1 | suspended | Jun 3, 2022 | University of Maryland, Baltimore | PI changed institution. Not yet approved at current location. | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT07075627 | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic… | — | withdrawn | Jul 20, 2025 | Addario Lung Cancer Medical Institute | Sponsor/Funder decision | Other (stated, no rule matched) |
| NCT03662074 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small… | Phase 2 | terminated | Sep 7, 2018 | Wake Forest University Health Sciences | After interim analysis decided not to move forward with continuing the trial. | Efficacy / futility |
| NCT05058651 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy… | Phase 2 / Phase 3 | suspended | Sep 28, 2021 | National Cancer Institute (NCI) | End of Initial Phase of Multi-phase protocol | Other (stated, no rule matched) |
| NCT01876771 | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in… | Phase 2 | suspended | Jun 13, 2013 | AHS Cancer Control Alberta | Study closed to accrual given widespread availability of the similar marketed product,… | Enrollment / accrual |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Washington University School of Medicine | Polaris has decided to close to accrual due to low enrollment | Enrollment / accrual |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small… | Phase 2 | withdrawn | Jan 18, 2018 | City of Hope Medical Center | No patients enrolled | Enrollment / accrual |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small… | Phase 1 | terminated | Apr 18, 2023 | Debiopharm International SA | The trial was concluded for strategic reasons. | Sponsor / business decision |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT06732258 | Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab… | Phase 1 | withdrawn | Dec 13, 2024 | Sichuan University | Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering… | Safety / toxicity |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With… | Phase 2 | terminated | Mar 27, 2025 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate… | Phase 1 / Phase 2 | withdrawn | Jan 9, 2026 | National Cancer Institute (NCI) | Study drug supplier withdrew support; no participants were enrolled. | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | Phase 1 / Phase 2 | terminated | Apr 22, 2025 | Ariceum Therapeutics GmbH | Study terminated due to strategic business decisions. | Sponsor / business decision |
| NCT05223647 | Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer(TRIPLEX) | Phase 3 | terminated | Feb 4, 2022 | Norwegian University of Science and Technology | Termination was adviced by Data Safety Committee due to excess toxicity of the experimental… | Safety / toxicity |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT04373369 | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | Phase 2 | terminated | May 4, 2020 | Washington University School of Medicine | Insufficient Funding/Staff | Funding |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Phase 1 / Phase 2 | terminated | Apr 3, 2019 | NeoImmuneTech | Strategic decision by sponsor | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects… | Phase 1 | suspended | Jan 5, 2018 | Amgen | Study on enrollment hold, may potentially resume. No active subjects on trial. | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive… | Phase 1 / Phase 2 | terminated | Aug 29, 2023 | STCube, Inc. | Company strategy | Sponsor / business decision |
| NCT05420636 | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary… | Phase 2 | terminated | Jun 15, 2022 | Fox Chase Cancer Center | Closed to accrual due to low probability of successful outcomes | Enrollment / accrual |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT06140407 | Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung… | Phase 2 | terminated | Nov 20, 2023 | Vanderbilt-Ingram Cancer Center | Low accrual and Merck discontinuing funding and drug supply | Drug supply |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine… | Phase 2 | terminated | Jun 15, 2021 | Rahul Aggarwal | Funding | Funding |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer…(SCope-D1) | Phase 1 | terminated | May 3, 2021 | AstraZeneca | AstraZeneca has decided to stop further enrollment and the study was terminated when all patients… | Safety / toxicity |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Phase 1 / Phase 2 | terminated | Sep 24, 2019 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT03387592 | CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas(SENECA) | Phase 2 | terminated | Jan 2, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Efficacy endpoint not met according to first step of Briant-Day design | Efficacy / futility |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in… | Phase 1 / Phase 2 | withdrawn | May 25, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT04923776 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | Phase 2 | terminated | Jun 11, 2021 | Brian Henick, MD | Poor enrollment | Enrollment / accrual |
| NCT05049863 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With… | Phase 1 | terminated | Sep 20, 2021 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04951115 | A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly… | Phase 2 | terminated | Jul 6, 2021 | Weill Medical College of Cornell University | The study was terminated early due to low accrual. | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials